Rationale and design of the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository

Jason I. Koontz, Daniel Haithcock, Valerie Cumbea, Anthony Waldron, Kristie Stricker, Amy Hughes, Kent R Nilsson, Albert Sun, Jonathan P. Piccini, William E. Kraus, Geoffrey S. Pitt, Svati H. Shah, Patrick Hranitzky

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Disturbances in cardiac rhythm can lead to significant morbidity and mortality. Many arrhythmias are known to have a heritable component, but the degree to which genetic variation contributes to disease risk and morbidity is poorly understood. Methods and Results: The EPGEN is a prospective single-center repository that archives DNA, RNA, and protein samples obtained at the time of an electrophysiologic evaluation or intervention. To identify genes and molecular variants that are associated with risk for arrhythmic phenotypes, EPGEN uses unbiased genomic screening; candidate gene analysis; and both unbiased and targeted transcript, protein, and metabolite profiling. To date, EPGEN has successfully enrolled >1,500 subjects. The median age of the study population is 62.9 years; 35% of the subjects are female and 21% are black. To this point, the study population has been composed of patients who had undergone defibrillator (implantable cardioverter-defibrillator or cardiac resynchronization therapy defibrillator) implantation (45%), electrophysiology studies or ablation procedures (35%), and pacemaker implantation or other procedures (20%). The cohort has a high prevalence of comorbidities, including diabetes (33%), hypertension (73%), chronic kidney disease (26%), and peripheral vascular disease (13%). Conclusions: We have established a biorepository and clinical database composed of patients with electrophysiologic diseases. EPGEN will seek to (1) improve risk stratification, (2) elucidate mechanisms of arrhythmogenesis, and (3) identify novel pharmacologic targets for the treatment of heart rhythm disorders.

Original languageEnglish (US)
Pages (from-to)719-725
Number of pages7
JournalAmerican Heart Journal
Volume158
Issue number5
DOIs
StatePublished - Nov 1 2009
Externally publishedYes

Fingerprint

Electrophysiology
Defibrillators
Morbidity
Cardiac Resynchronization Therapy
Peripheral Vascular Diseases
Implantable Defibrillators
Genetic Association Studies
Chronic Renal Insufficiency
Population
Comorbidity
Cardiac Arrhythmias
Proteins
Databases
RNA
Hypertension
Phenotype
Mortality
DNA
Genes
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Koontz, J. I., Haithcock, D., Cumbea, V., Waldron, A., Stricker, K., Hughes, A., ... Hranitzky, P. (2009). Rationale and design of the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository. American Heart Journal, 158(5), 719-725. https://doi.org/10.1016/j.ahj.2009.08.011

Rationale and design of the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository. / Koontz, Jason I.; Haithcock, Daniel; Cumbea, Valerie; Waldron, Anthony; Stricker, Kristie; Hughes, Amy; Nilsson, Kent R; Sun, Albert; Piccini, Jonathan P.; Kraus, William E.; Pitt, Geoffrey S.; Shah, Svati H.; Hranitzky, Patrick.

In: American Heart Journal, Vol. 158, No. 5, 01.11.2009, p. 719-725.

Research output: Contribution to journalArticle

Koontz, JI, Haithcock, D, Cumbea, V, Waldron, A, Stricker, K, Hughes, A, Nilsson, KR, Sun, A, Piccini, JP, Kraus, WE, Pitt, GS, Shah, SH & Hranitzky, P 2009, 'Rationale and design of the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository', American Heart Journal, vol. 158, no. 5, pp. 719-725. https://doi.org/10.1016/j.ahj.2009.08.011
Koontz, Jason I. ; Haithcock, Daniel ; Cumbea, Valerie ; Waldron, Anthony ; Stricker, Kristie ; Hughes, Amy ; Nilsson, Kent R ; Sun, Albert ; Piccini, Jonathan P. ; Kraus, William E. ; Pitt, Geoffrey S. ; Shah, Svati H. ; Hranitzky, Patrick. / Rationale and design of the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository. In: American Heart Journal. 2009 ; Vol. 158, No. 5. pp. 719-725.
@article{642a4c4d30db4575845a74030d6025c1,
title = "Rationale and design of the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository",
abstract = "Background: Disturbances in cardiac rhythm can lead to significant morbidity and mortality. Many arrhythmias are known to have a heritable component, but the degree to which genetic variation contributes to disease risk and morbidity is poorly understood. Methods and Results: The EPGEN is a prospective single-center repository that archives DNA, RNA, and protein samples obtained at the time of an electrophysiologic evaluation or intervention. To identify genes and molecular variants that are associated with risk for arrhythmic phenotypes, EPGEN uses unbiased genomic screening; candidate gene analysis; and both unbiased and targeted transcript, protein, and metabolite profiling. To date, EPGEN has successfully enrolled >1,500 subjects. The median age of the study population is 62.9 years; 35{\%} of the subjects are female and 21{\%} are black. To this point, the study population has been composed of patients who had undergone defibrillator (implantable cardioverter-defibrillator or cardiac resynchronization therapy defibrillator) implantation (45{\%}), electrophysiology studies or ablation procedures (35{\%}), and pacemaker implantation or other procedures (20{\%}). The cohort has a high prevalence of comorbidities, including diabetes (33{\%}), hypertension (73{\%}), chronic kidney disease (26{\%}), and peripheral vascular disease (13{\%}). Conclusions: We have established a biorepository and clinical database composed of patients with electrophysiologic diseases. EPGEN will seek to (1) improve risk stratification, (2) elucidate mechanisms of arrhythmogenesis, and (3) identify novel pharmacologic targets for the treatment of heart rhythm disorders.",
author = "Koontz, {Jason I.} and Daniel Haithcock and Valerie Cumbea and Anthony Waldron and Kristie Stricker and Amy Hughes and Nilsson, {Kent R} and Albert Sun and Piccini, {Jonathan P.} and Kraus, {William E.} and Pitt, {Geoffrey S.} and Shah, {Svati H.} and Patrick Hranitzky",
year = "2009",
month = "11",
day = "1",
doi = "10.1016/j.ahj.2009.08.011",
language = "English (US)",
volume = "158",
pages = "719--725",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Rationale and design of the Duke Electrophysiology Genetic and Genomic Studies (EPGEN) biorepository

AU - Koontz, Jason I.

AU - Haithcock, Daniel

AU - Cumbea, Valerie

AU - Waldron, Anthony

AU - Stricker, Kristie

AU - Hughes, Amy

AU - Nilsson, Kent R

AU - Sun, Albert

AU - Piccini, Jonathan P.

AU - Kraus, William E.

AU - Pitt, Geoffrey S.

AU - Shah, Svati H.

AU - Hranitzky, Patrick

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Background: Disturbances in cardiac rhythm can lead to significant morbidity and mortality. Many arrhythmias are known to have a heritable component, but the degree to which genetic variation contributes to disease risk and morbidity is poorly understood. Methods and Results: The EPGEN is a prospective single-center repository that archives DNA, RNA, and protein samples obtained at the time of an electrophysiologic evaluation or intervention. To identify genes and molecular variants that are associated with risk for arrhythmic phenotypes, EPGEN uses unbiased genomic screening; candidate gene analysis; and both unbiased and targeted transcript, protein, and metabolite profiling. To date, EPGEN has successfully enrolled >1,500 subjects. The median age of the study population is 62.9 years; 35% of the subjects are female and 21% are black. To this point, the study population has been composed of patients who had undergone defibrillator (implantable cardioverter-defibrillator or cardiac resynchronization therapy defibrillator) implantation (45%), electrophysiology studies or ablation procedures (35%), and pacemaker implantation or other procedures (20%). The cohort has a high prevalence of comorbidities, including diabetes (33%), hypertension (73%), chronic kidney disease (26%), and peripheral vascular disease (13%). Conclusions: We have established a biorepository and clinical database composed of patients with electrophysiologic diseases. EPGEN will seek to (1) improve risk stratification, (2) elucidate mechanisms of arrhythmogenesis, and (3) identify novel pharmacologic targets for the treatment of heart rhythm disorders.

AB - Background: Disturbances in cardiac rhythm can lead to significant morbidity and mortality. Many arrhythmias are known to have a heritable component, but the degree to which genetic variation contributes to disease risk and morbidity is poorly understood. Methods and Results: The EPGEN is a prospective single-center repository that archives DNA, RNA, and protein samples obtained at the time of an electrophysiologic evaluation or intervention. To identify genes and molecular variants that are associated with risk for arrhythmic phenotypes, EPGEN uses unbiased genomic screening; candidate gene analysis; and both unbiased and targeted transcript, protein, and metabolite profiling. To date, EPGEN has successfully enrolled >1,500 subjects. The median age of the study population is 62.9 years; 35% of the subjects are female and 21% are black. To this point, the study population has been composed of patients who had undergone defibrillator (implantable cardioverter-defibrillator or cardiac resynchronization therapy defibrillator) implantation (45%), electrophysiology studies or ablation procedures (35%), and pacemaker implantation or other procedures (20%). The cohort has a high prevalence of comorbidities, including diabetes (33%), hypertension (73%), chronic kidney disease (26%), and peripheral vascular disease (13%). Conclusions: We have established a biorepository and clinical database composed of patients with electrophysiologic diseases. EPGEN will seek to (1) improve risk stratification, (2) elucidate mechanisms of arrhythmogenesis, and (3) identify novel pharmacologic targets for the treatment of heart rhythm disorders.

UR - http://www.scopus.com/inward/record.url?scp=70350233481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350233481&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2009.08.011

DO - 10.1016/j.ahj.2009.08.011

M3 - Article

VL - 158

SP - 719

EP - 725

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -